Universal Health Services (UHS)
(Delayed Data from NYSE)
$224.66 USD
-4.35 (-1.90%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $224.60 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$224.66 USD
-4.35 (-1.90%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $224.60 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Zacks News
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
by Zacks Equity Research
QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.
iRhythm Technologies Launches Zio Monitoring Across Europe
by Zacks Equity Research
IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.
Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Relative Price Strength Stocks That You Should Buy Now
by Nilanjan Choudhury
SNCR, MCY, UHS, VCYT and MWA are five stocks with explosive relative price strength.
Veeva Systems Q2 Earnings & Revenues Beat, Operating Margin Up Y/Y
by Zacks Equity Research
VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
by Zacks Equity Research
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
Tenet Stock Rises 24.6% in 3 Months: Is This Your Buy Signal?
by Kaibalya Pravo Dey
Despite the recent growth in stock price, THC is trading at a discount compared to the industry average.
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
by Zacks Equity Research
ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
Stryker Rallies 19.8% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
by Zacks Equity Research
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch
by Zacks Equity Research
DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.
Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024
by Zacks Equity Research
GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes
by Zacks Equity Research
Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
by Zacks Equity Research
Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
by Zacks Equity Research
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare
by Zacks Equity Research
Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.
Why Is Universal Health Services (UHS) Up 11.9% Since Last Earnings Report?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio
by Zacks Equity Research
Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.
Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.